Intercept reaches major end in phase 3 trial of new drug Ocacic acid (OCA)
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
NASH is a progressive liver disease caused by excessive accumulation of fat in the liver, which can lead to chronic inflammation of the liver, trigger progressive liver fibrosis, cirrhosis, and ultimately lead to liver failure, cancer, and deathtoday, the(http://of Interceptannounced that its non-alcoholic fatty hepatitis (NASH) had reached its main endpoint in a phase 3trial(http://of thenew drug(http://) obeticacid acid ( OCA) in a phase 3 trialThis promises to lead to the first new drug to treat NASH!About OCA
Intercept developed OCA is a faniol X receptor (farnesoid X receptor, FXR) agonist, while FXR is involved in important metabolic processes such as bile acid metabolism and cholesterol metabolismIt has also been recognized by the U.SFDA(http://for its therapeutic potential in patients with liver fibrosis NASHThe results of this clinical trial further confirm this potentialIn this randomized double-blind, placebo-controlled multicenter trial, 931 NASH patients with stage 2 or 3 liver fibrosis were divided into three groups and treated with different doses of OCA (10 mg or 25 mg) or placebothe interim dataanalysis of(http://, the results showed that after 18 months of treatment, the daily OCA (25 mg) reached the main endpoint of the trial: a significant improvement in the patient's liver fibrosis compared to placebo (fibrosis improved by more than 1 level, p.0002)At the same time, the patient's NASH symptoms did not deteriorate significantly
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
